as 10-21-2024 4:00pm EST
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Founded: | 2017 | Country: | United States |
Employees: | N/A | City: | REDWOOD CITY |
Market Cap: | 275.6M | IPO Year: | 2021 |
Target Price: | $36.33 | AVG Volume (30 days): | 1.1M |
Analyst Decision: | Buy | Number of Analysts: | 13 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.90 | EPS Growth: | N/A |
52 Week Low/High: | $3.61 - $22.74 | Next Earning Date: | 11-01-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Hitchcock Michael J.M. | BMEA | Director | Sep 30 '24 | Buy | $10.06 | 10,000 | $100,600.00 | 15,000 |
BMEA Breaking Stock News: Dive into BMEA Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 hours ago
GlobeNewswire
6 days ago
TipRanks
12 days ago
GlobeNewswire
15 days ago
Simply Wall St.
19 days ago
Argus Research
20 days ago
GlobeNewswire
21 days ago
Benzinga
25 days ago
The information presented on this page, "BMEA Biomea Fusion Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.